Small molecule inhibition of NOTCH3 conformational alterations

Awardee: Michael Wang

Institution: University of Michigan

Grant Amount: $101,776

Funding Period: February 1, 2025 - January 31, 2026


Summary:

CADASIL is the leading inherited cause of stroke and vascular dementia and is caused by mutations in NOTCH3. Mutations in NOTCH3 result in abnormal conformations of NOTCH3 protein. We reason that drugs that reverse the abnormal conformations of NOTCH3 may be beneficial to patients. This project aims to perform a drug screen to identify chemicals that bind to mutant NOTCH3 and, by doing so, coax it into a more normal conformation. Towards this goal, we have devised a new technique which will help screen through rationally selected drug candidates. If successful, this would be a first step in drug discovery for CADASIL, currently an untreatable disease.

Previous
Previous

Development of glycogen synthase inhibitors for APBD

Next
Next

Understanding the role of the lipid transport protein VPS13B in Cohen syndrome pathogenesis